Legal & General Group PLC Krystal Biotech, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 68,164 shares of KRYS stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,164

Previous 68,164 -0.0%

Holding current value

$10.7 Million

Previous $12.4 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $360,056 - $440,353	2,061 Added 3.12%	68,164 $12.4 Million
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $7.13 Million - $8.55 Million	46,553 Added 238.12%	66,103 $12.1 Million
Q1 2024 Jul 01, 2024	BUY	$108.01 - $179.35 $89,648 - $148,860	830 Added 4.43%	19,550 $3.48 Million
Q1 2024 May 14, 2024	SELL	$108.01 - $179.35 $40,179 - $66,718	-372 Reduced 1.95%	18,720 $3.33 Million
Q4 2023 Feb 15, 2024	SELL	$96.0 - $128.29 $41,760 - $55,806	-435 Reduced 2.23%	19,092 $2.37 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $89,086 - $106,910	821 Added 4.39%	19,527 $2.27 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $742,185 - $1.23 Million	9,457 Added 102.25%	18,706 $2.2 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $154,118 - $179,410	2,129 Added 29.9%	9,249 $740,000
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $9,786 - $12,384	155 Added 2.23%	7,120 $564,000
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $25,096 - $31,888	387 Added 5.88%	6,965 $485,000
Q2 2022 Aug 22, 2022	BUY	$48.93 - $73.47 $2,201 - $3,306	45 Added 0.69%	6,578 $431,000
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $19,236 - $26,680	370 Added 6.0%	6,533 $435,000
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $22,612 - $50,120	568 Added 10.15%	6,163 $432,000
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $146,460 - $202,104	2,816 Added 101.33%	5,595 $293,000
Q2 2021 Aug 12, 2021	BUY	$62.14 - $81.82 $6,773 - $8,918	109 Added 4.08%	2,779 $189,000
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $16,697 - $24,014	281 Added 11.76%	2,670 $206,000
Q3 2020 Nov 13, 2020	SELL	$37.76 - $48.49 $13,404 - $17,213	-355 Reduced 12.94%	2,389 $102,000
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $10,109 - $16,380	273 Added 11.05%	2,744 $113,000
Q1 2020 May 14, 2020	SELL	$35.02 - $65.64 $16,424 - $30,785	-469 Reduced 15.95%	2,471 $107,000
Q4 2019 Feb 13, 2020	BUY	$33.17 - $65.23 $13,732 - $27,005	414 Added 16.39%	2,940 $163,000
Q3 2019 Nov 13, 2019	BUY	$34.72 - $51.3 $37,011 - $54,685	1,066 Added 73.01%	2,526 $88,000
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $39,712 - $60,152	1,460 New	1,460 $59,000

Others Institutions Holding KRYS

# of Institutions

311

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.02B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Krystal Biotech, Inc. Transaction History